K.J. Harrison & Partners Inc lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 33.2% during the third quarter, Holdings Channel reports. The fund owned 62,011 shares of the company’s stock after purchasing an additional 15,451 shares during the quarter. Johnson & Johnson accounts for 2.8% of K.J. Harrison & Partners Inc’s investment portfolio, making the stock its 2nd largest holding. K.J. Harrison & Partners Inc’s holdings in Johnson & Johnson were worth $8,062,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 1.5% during the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after acquiring an additional 3,023,110 shares during the last quarter. BlackRock Inc. increased its position in shares of Johnson & Johnson by 2.6% during the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after acquiring an additional 4,332,612 shares during the last quarter. FMR LLC increased its position in shares of Johnson & Johnson by 5.9% during the second quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after acquiring an additional 1,509,745 shares during the last quarter. Capital World Investors grew its stake in Johnson & Johnson by 4.1% in the second quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock worth $3,507,009,000 after purchasing an additional 1,050,000 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its stake in Johnson & Johnson by 4.5% in the second quarter. Ameriprise Financial Inc. now owns 17,860,047 shares of the company’s stock worth $2,363,788,000 after purchasing an additional 771,039 shares in the last quarter. 65.70% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson (NYSE:JNJ) opened at $145.76 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 52 week low of $110.76 and a 52 week high of $146.42. The company has a market capitalization of $391,590.00, a P/E ratio of 25.31, a price-to-earnings-growth ratio of 2.73 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. During the same period in the previous year, the firm posted $1.68 earnings per share. Johnson & Johnson’s quarterly revenue was up 10.3% compared to the same quarter last year. equities research analysts predict that Johnson & Johnson will post 7.28 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be paid a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.31%. Johnson & Johnson’s payout ratio is currently 58.33%.

JNJ has been the subject of a number of research reports. Cowen reiterated an “outperform” rating and issued a $155.00 price target (up from $147.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Jefferies Group lifted their price target on Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, October 16th. Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the stock an “outperform” rating in a research note on Thursday, October 19th. Finally, Barclays lifted their price target on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Hold” and a consensus target price of $145.94.

ILLEGAL ACTIVITY NOTICE: “K.J. Harrison & Partners Inc Acquires 15,451 Shares of Johnson & Johnson (JNJ)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/01/14/k-j-harrison-partners-inc-acquires-15451-shares-of-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.